Clinical Research Directory
Browse clinical research sites, groups, and studies.
Medico-economic Evaluation of Therapeutic Adaptation Guided by the Soluble Suppression of Tumorigenicity 2 (sST-2) Biomarker in the Management of Patients With Acute Heart Failure
Sponsor: University Hospital, Montpellier
Summary
Management of patients with heart Failure remains a major health concern because of the high rate of rehospitalization, mortality and induced-cost. Biomarkers could help to guide the management of patients with heart failure (HF). Soluble suppression of tumorigenicity 2 (sST2) appears as a promising biomarker. As a working hypothesis, we postulate that sST2 values monitoring could be an helpful guide for medical management in an attempt to reduce hospital readmission.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
710
Start Date
2021-04-27
Completion Date
2027-01
Last Updated
2025-09-30
Healthy Volunteers
No
Conditions
Interventions
Biomarker guided therapy
Guided therapy using sST-2 monitoring at the discharge from initial hospitalisation, 6, 12, 18 and 24 months of following.
Locations (12)
Lapeyronie Hospital
Montpellier, Occitanie, France
CHU Angers
Angers, France
CHU Besançon
Besançon, France
CH Béziers
Béziers, France
CHU Caen
Caen, France
CHU Grenoble
Grenoble, France
Arnaud de Villeneuve Hospital
Montpellier, France
CHU Nimes
Nîmes, France
APHP Pompidou
Paris, France
CHU Rennes
Rennes, France
CHU Toulouse
Toulouse, France
CHU Vannes
Vannes, France